Syndax Pharmaceuticals, Inc.

SNDX

NASDAQHealthcareBiotechnology

在 GoAI 中打开

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

47/ 100

GoAI评分

Hold

Wait — insufficient conviction to act

估值

Expensive

动量

Gaining

情绪

Mixed

风险韧性

Moderate Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考，并非投资建议。

公司概况

公司网站

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

行业: Biotechnology
部门: Healthcare
总部: US
首席执行官: Michael A. Metzger
上市以来: 2016年3月2日
雇员: 298